DIAGNOS Gets the Green Light for the Use of its Diabetic Retinopathy Screening Technology in Quebec Hospitals
January 31 2023 - 10:04AM
Diagnos Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce that the Quebec
government has given the green light to Diagnos' Artificial
Intelligence (AI) technology to screen and assess Diabetic
Retinopathy of patients served by the endocrinology departments of
hospitals across the province.
This positive milestone comes as the result of a
collaboration project initiated in 2018, where Diagnos’ technology
was utilized to screen and classify the level severity of the
Diabetic Retinopathy disease in patients of the endocrinology
department from a major Quebec Hospital.
The pilot phase of the project has been
successfully concluded, resulting in the production of a final
report by government officials. This report has been disseminated
to all hospitals in the province, highlighting the cost savings and
other benefits of implementing DIAGNOS' technology. Specifically,
the report found that using DIAGNOS' technology resulted in cost
savings of $85 per patient, as well as additional savings from the
optimization and reduction of time required from healthcare
workers.
“The project has been a long but rewarding
journey for DIAGNOS, especially in light of the COVID-19
restrictions in the hospital departments of Endocrinology and
Ophthalmology. We are overjoyed by the government’s acknowledgement
of the value of our AI-based Diabetic Retinopathy screening
solution. DIAGNOS will now begin commercializing it to all
hospitals and clinics in the province," says Mr.
André Larente, President of DIAGNOS.
Larente further adds "We have been working
tirelessly on this project since 2018, and we are excited to bring
Diagnos’ innovative solutions to the population of Quebec,
especially considering the high rate of diabetes in the province.
Our solutions will make early detection and prevention of vision
loss more accessible to the population, which is crucial for the
health and well-being of those living with diabetes."
According to Statistics Canada, Quebec has one
of the highest rates of diabetes in the country, with over 1
million people living with diabetes. With such a large population
of diabetic patients receiving endocrinology services at Quebec
hospitals, the market potential for DIAGNOS' AI screening solutions
is significant.
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450
678-8882, ext. 224Email: alarente@diagnos.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/87001ed4-5039-44c7-a5aa-dc862016216b
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024